Zymeworks advances with strong Phase III Ziihera data, royalty-driven growth, solid cash, updated buy and sell levels. See ...

As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...

Praxis Precision Medicines, Inc. ( PRAX) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST All right. We're going to get started with our next session. I'm Andrew Tsai, Senior ...

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with ...

The ATTRibute-CM study's open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with ...

For decades, one of the most widely prescribed pregnancy drugs has been used on faith: doctors knew it helped sustain early ...

On August 18, 2025, Enlivex announced the 3-month topline data, reporting that Allocetra™ demonstrated, in the primary age group (60+), substantial reduction in pain and improvement in function across ...

Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...

Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene ...

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...